Logiscreen

Phio Pharmaceuticals Corp

$1.09
Market Cap 12.66M
ROE -77.3%
Gross Margin 0.0%
Debt/Equity 0.0
Current Ratio 18.3
Revenue QoQ 0.0%
EPS QoQ -0.2%
F-Score 1

About

Phio Pharmaceuticals Corp. is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-1.16
vs median 34.32
P/B
0.77
vs median 2.21
ROE
-0.77
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics